Results from a randomized, controlled trial evaluating liraglutide for adolescents with obesity were published on 2020-01-01 in the New England Journal of Medicine. The study investigated the effect of liraglutide for weight management in pubertal adolescent subjects with obesity.
Background
The published trial investigated liraglutide for weight management in pubertal adolescent subjects with obesity. Liraglutide is known by several aliases, including Xultophy 100/3.6, Saxenda, and Victoza. It is also available in formulations with insulin degludec.
Trial design
The study was described as a randomized, controlled trial. It focused on evaluating liraglutide for adolescents with obesity, specifically pubertal adolescent subjects, with the goal of assessing its effect on weight management.
What this means
The publication of these trial results makes the findings on liraglutide for weight management in pubertal adolescents with obesity available to the scientific and medical community. While specific outcome data is not detailed in the provided information, the publication of a randomized, controlled trial in a peer-reviewed journal indicates that data regarding the effect of liraglutide in this population has been formally presented. Clinicians and researchers can now access the full study to understand the efficacy and safety profile of liraglutide for this indication.
Source
The information regarding this trial publication was sourced from PubMed. The article, titled 'A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity', was published on 2020-01-01 in the New England Journal of Medicine and is accessible via pubmed.ncbi.nlm.nih.gov.